Simple problem Zut is that the majority target market for GMV would have been around treatment of BP and heart conditions. During the time frame of the last 18-24 months when Yacov and crew have met various difficulties the rest of the market has caught up to them. Ask yourself this - what's easier a watch that can read biorhythms and critical data without you doing anything extra or a product you have to pull out and attach to?
Yacov's dream is over due to him and his team dragging the chain. Long Term Hold will equal LT loss. Get out when you can. AIMHO
- Forums
- ASX - By Stock
- GMV
- Ann: Trading Halt
Ann: Trading Halt, page-76
-
- There are more pages in this discussion • 99 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GMV (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online